Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 22, 2026

Will EV Stocks Make a Comeback in 2026?

View original at nasdaq.com
Will EV Stocks Make a Comeback in 2026? In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Rivian’s R2 launch.The decline of EVs in the U.S.Will autonomy be a value add for EV companies?Hidden gems in the EV market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rivian is pursuing the R2 with the bill of materials at about half the cost of the R1S, intending it to be a margin driver rather than simply a volume/market-share play.

    60% confidence
  • NXP Semiconductors dominates the automotive processing and battery management systems market with mission-critical microcontrollers required by major global automakers, positioning it as a profitable, diversified beneficiary of ADAS growth.

    60% confidence
  • General Motors' stock has outperformed Rivian, Tesla, Lucid, and QuantumScape over the past three years while trading at just six times forward earnings, suggesting the 'obvious' legacy automaker answer may be the real hidden gem.

    60% confidence
  • Autonomy software is not going to be a meaningful growth avenue that differentiates EV companies from legacy automakers.

    60% confidence
  • Autonomy and driver-assist features will follow the historical pattern of premium features becoming commoditized standard features, as happened with windshield wipers, adaptive cruise control, and leather seats.

    60% confidence
  • It's unclear how much of the EV sales drop-off is due to the end of the tax credit versus early adopters already having bought in and the market not yet being mainstream.

    60% confidence
  • Autonomous driving software faces a 'severe 99% problem' — handling standard highway driving is solvable, but mastering the final 1% of chaotic, unpredictable urban edge cases requires computing power and sophistication that many EV start-ups and automakers cannot reliably deliver on a guaranteed timeline.

    60% confidence
  • Rivian is trying to make the R2 into 'the Subaru of the EV market' by offering a premium, feature-loaded soft-road product at a lower price point.

    60% confidence
  • Secondary market supply of used EVs is very high as early-adopter leased/purchased EVs flood the market, which could drive used EV prices toward parity with gas cars within about five years and may cannibalize new car demand.

    60% confidence
  • Hardware redundancy needed for autonomy (LiDAR, dual superchip processors, redundant braking/steering) creates significant capital costs that weigh on corporate profitability and trickle down to consumer prices.

    60% confidence
  • QuantumScape's solid-state battery technology, if it can be mass-produced at scale, would be the breakthrough needed to trigger a real EV revolution by enabling more stable, faster-charging batteries.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Will EV Stocks Make a Comeback in 2026? — Source | Via News | Finance Via News